Ex-vivo active immunotherapy against infectious diseases and tumoral antigens for mimicking natural production by b cells of immunoglobulin

The present invention concerns lentiviral vectors enabling the expression of membrane-anchored and secreted antibodies by B cells. This invention results from the development of a new method for adoptive transfer of B-cells transduced with a lentiviral vector (LV) conditionally expressing the secreted or the membrane-anchored form (BCR) of a transgenic immunoglobulin of interest, depending on the maturation status of transduced B-cells. Engineered B-cells producing an ectopic immunoglobulin of interest for ex vivo active immunotherapy, allow long-term memory immune response.

Keywords: infectious diseases, Oncology, lentivirus, vectors, multicistronic, BCR, immunoprophylaxis, ex-vivo therapy, FAM2, immunotherapy
Patent Application number: EP15306132.0
Inventors:
Thierry DEFRANCEFloriane FUSILFrançois-Loïc COSSETEls VERHOEYEN
Publications:
Mol Ther. 2015 Nov;23(11):1734-1747. doi: 10.1038/mt.2015.148. Epub 2015 Aug 18.

Reference:

BIO15066-T1

Business Developper
contact
Inserm Transfert
Inserm Transfert
Business Developer
Patent filling date: 2015-07-09

You might also be interested in